Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Minophagen licenses Eisai two hepatic disease drugs

Executive Summary

Minophagen Pharmaceutical licensed fellow Japanese pharmaco Eisai exclusive rights to develop and market two liver disease drugs--Stronger Neo-Minophagen C and Glycyron (both forms of glycyrrhizinate)--in Japan, Singapore, the Philippines, Hong Kong, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, Laos, Brunei, Australia, Russia, Jordan, Saudi Arabia, Kuwait, United Arab Emirates, and Yemen.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies